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Background
Patients with advanced NSCLC are treated with first-line
PT-DC, which is associated with a median OS of 8–10
months and 1-year and 2-year survival rates of 30–40%
and 10–15%, respectively. Nivolumab (a fully human IgG4
anti-programmed death-1 immune checkpoint inhibitor
antibody) alone and in combination with ipilimumab
(a fully human IgG4 cytotoxic T-lymphocyte antigen-4
immune checkpoint inhibitor antibody) has demonstrated
encouraging clinical benefit across multiple tumor types.
Two randomized Phase III trials demonstrated superior
survival with nivolumab vs docetaxel in previously-treated
patients with advanced squamous (SQ) (CheckMate 017)
and non-squamous (non-SQ) NSCLC (CheckMate 057).
Preliminary results of a Phase I study (CheckMate 012) of
nivolumab with or without ipilimumab demonstrate
acceptable safety and encouraging activity in first-line
metastatic NSCLC across histologies. This Phase III trial
(CheckMate 227) evaluates nivolumab monotherapy and
nivolumab plus ipilimumab combination regimens vs
PT-DC in patients with chemotherapy-naïve stage IV or
recurrent SQ and non-SQ NSCLC.
Methods
Adult patients with stage IV or recurrent NSCLC,
ECOG performance status ≤1, no prior systemic anti-
cancer therapy, and measureable disease per RECIST
version 1.1 are eligible. Tissue will be evaluated for pro-
grammed death-ligand 1 (PD-L1) expression during
screening. Patients who have untreated CNS metastases
are ineligible. Patients will be randomized to nivolumab
monotherapy, nivolumab plus ipilimumab combination
regimens, or PT-DC. PT-DC will be administered
according to histology (gemcitabine with cisplatin or
carboplatin for SQ and pemetrexed with cisplatin or
carboplatin for non-SQ). Patients will receive treatment
until progression or unacceptable toxicity. The co-primary
endpoints are overall survival and progression-free survival
in patients receiving nivolumab monotherapy or nivolu-
mab plus ipilimumab combination regimens vs patients
receiving PT-DC. Secondary endpoints include objective
response rate in nivolumab monotherapy or nivolumab
plus ipilimumab combination regimens vs PT-DC and dis-
ease related symptom improvement measured by the
Lung Cancer Symptom Scale in all patients.
Trial registration
ClinicalTrials.gov identifier NCT02477826.
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
Full list of author information is available at the end of the article
Hellmann et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P154
http://www.immunotherapyofcancer.org/content/3/S2/P154
© 2015 Hellmann et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ details
1Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2Winship
Cancer Institute, Emory University, Atlanta, GA, USA. 3Krankenhaus
Grosshansdorf Gmbh, Ahrensburg, Germany. 4Cancer Services, Princess
Alexandra Hospital, Brisbane, QLD, Australia. 5Hospital Universitario Virgen del
Rocio, Sevilla, Spain. 6Bristol-Myers Squibb, Princeton, NJ, USA. 7Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD,
USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P154
Cite this article as: Hellmann et al.: An open label randomized Phase III
trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet
chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or
recurrent non-small cell lung cancer (NSCLC) (CheckMate 227). Journal
for ImmunoTherapy of Cancer 2015 3(Suppl 2):P154.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hellmann et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P154
http://www.immunotherapyofcancer.org/content/3/S2/P154
Page 2 of 2
